316 related articles for article (PubMed ID: 8328566)
1. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
Schweizer E; Patterson W; Rickels K; Rosenthal M
Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
[TBL] [Abstract][Full Text] [Related]
2. Diazepam versus alprazolam for the treatment of panic disorder.
Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.
Pecknold J; Luthe L; Munjack D; Alexander P
J Clin Psychopharmacol; 1994 Oct; 14(5):314-21. PubMed ID: 7806686
[TBL] [Abstract][Full Text] [Related]
4. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
Klein E; Colin V; Stolk J; Lenox RH
Am J Psychiatry; 1994 Dec; 151(12):1760-6. PubMed ID: 7977882
[TBL] [Abstract][Full Text] [Related]
5. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
[TBL] [Abstract][Full Text] [Related]
6. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.
Lydiard RB; Lesser IM; Ballenger JC; Rubin RT; Laraia M; DuPont R
J Clin Psychopharmacol; 1992 Apr; 12(2):96-103. PubMed ID: 1573046
[TBL] [Abstract][Full Text] [Related]
7. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper.
Rickels K; Schweizer E; Weiss S; Zavodnick S
Arch Gen Psychiatry; 1993 Jan; 50(1):61-8. PubMed ID: 8422223
[TBL] [Abstract][Full Text] [Related]
8. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.
Pecknold JC; Swinson RP; Kuch K; Lewis CP
Arch Gen Psychiatry; 1988 May; 45(5):429-36. PubMed ID: 3282479
[TBL] [Abstract][Full Text] [Related]
9. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study.
Sheehan DV; Raj AB; Harnett-Sheehan K; Soto S; Knapp E
Acta Psychiatr Scand; 1993 Jul; 88(1):1-11. PubMed ID: 8372689
[TBL] [Abstract][Full Text] [Related]
10. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
Schweizer E; Rickels K; Weiss S; Zavodnick S
Arch Gen Psychiatry; 1993 Jan; 50(1):51-60. PubMed ID: 8422222
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation reactions to alprazolam in panic disorder.
Pecknold JC
J Psychiatr Res; 1993; 27 Suppl 1():155-70. PubMed ID: 8145176
[TBL] [Abstract][Full Text] [Related]
12. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
[TBL] [Abstract][Full Text] [Related]
13. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo.
Pollack MH; Otto MW; Sachs GS; Leon A; Shear MK; Deltito JA; Keller MB; Rosenbaum JF
J Affect Disord; 1994 Apr; 30(4):273-81. PubMed ID: 8014326
[TBL] [Abstract][Full Text] [Related]
14. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
[TBL] [Abstract][Full Text] [Related]
15. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
Greenblatt DJ; Harmatz JS; Shader RI
Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
[TBL] [Abstract][Full Text] [Related]
16. Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.
Carter CS; Fawcett J; Hertzman M; Papp LA; Jones W; Patterson WM; Swinson RP; Weise CC; Maddock RJ; Denahan AQ
J Clin Psychiatry; 1995 May; 56(5):202-10. PubMed ID: 7737960
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder.
Tesar GE; Rosenbaum JF; Pollack MH; Otto MW; Sachs GS; Herman JB; Cohen LS; Spier SA
J Clin Psychiatry; 1991 Feb; 52(2):69-76. PubMed ID: 1993639
[TBL] [Abstract][Full Text] [Related]
18. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.
Ballenger JC; Burrows GD; DuPont RL; Lesser IM; Noyes R; Pecknold JC; Rifkin A; Swinson RP
Arch Gen Psychiatry; 1988 May; 45(5):413-22. PubMed ID: 3282478
[TBL] [Abstract][Full Text] [Related]
19. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
[TBL] [Abstract][Full Text] [Related]
20. Adinazolam sustained-release treatment of panic disorder: a double-blind study.
Davidson JR; Beitman B; Greist JH; Maddock RJ; Lewis CP; Sheridan AQ; Carter C; Krishnan KR; Liebowitz MR; Haack DG
J Clin Psychopharmacol; 1994 Aug; 14(4):255-63. PubMed ID: 7962681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
